Where to buy CJC-1295.

A 2026 sourcing guide for CJC-1295 — the GHRH analog with two distinct variants (DAC and no-DAC), a discontinued clinical development program, a WADA prohibition that funded its own analytical-chemistry literature, and the specific identity-verification questions every research buyer should ask before purchase.

Buying guide9 min read

Key takeaway

CJC-1295 mimics the body’s growth-hormone-releasing hormone. Two forms exist. No-DAC, also called Modified GRF 1-29, has a 30-minute window of action. DAC adds a chemical linker that binds blood albumin and stretches the window to 6–8 days. The DAC program shut down in 2007. On November 17, 2026, US research suppliers listed no-DAC 5 mg vials at $20.00–$46.00. The DAC form usually costs more. WADA bans both. The common buying mistake: grabbing a vial labeled only “CJC-1295.”

At a glance

Article typeBuying guide
Main guideCJC-1295: complete guide
Regulatory statusNot FDA-approved“CJC-1295 isn't approved by the FDA, the EMA, or any other major regulator for any condition” (CJC-1295: complete guide)
ClassGrowth hormone axis
Body systemsEndocrine & metabolism
Studies cited7 in this article · 22 across 7 articles on CJC-1295
ProductCJC-1295 product page

There are two molecules sold under the name CJC-1295, and they aren’t the same drug. One has a 30-minute half-life. The other lasts 6–8 days. The difference is a small chemical add-on called DAC. If a vendor labels a vial just “CJC-1295” without telling you which form you’re getting, that’s the first red flag. We’ll walk you through the rest.

Get new research first

Research updates
Citation-anchored summaries New-batch COA alerts Unsubscribe anytime

One short email when new peptide research drops or a new lab-verified batch lands — written from primary sources, no filler.

Quick answer: On November 17, 2026, US research suppliers listed no-DAC 5 mg vials at $20.00–$46.00. Confirm the label says “no-DAC” or “DAC” explicitly. Demand a Certificate of Analysis (CoA) from an ISO 17025 lab (an international testing-quality standard) with HPLC purity above 98% and a mass-spec result matching the variant. For no-DAC, that’s 3367.9 g/mol.

What you’re actually buying

CJC-1295 mimics the first 29 amino acids of human growth-hormone-releasing hormone — the brain signal that triggers GH pulses. ConjuChem developed it in the early 2000s as a once-weekly drug candidate (Rahman et al., 2026).

It activates the GH pathway in the pituitary. It does not bind the ghrelin pathway — that’s ipamorelin’s job. That’s why researchers stack the two together rather than choose one.

The thing that decides which CJC-1295 you have is the DAC group. DAC stands for Drug Affinity Complex. It’s a small chemical linker that covalently bonds to albumin in blood (Memdouh et al., 2021). Albumin acts like a slow-release shuttle. Once the peptide is bound to it, the kidneys can’t filter it out fast.

  • No-DAC (Modified GRF 1-29): 29 amino acids, half-life ~30 minutes, produces natural GH pulses.
  • DAC: 30 amino acids plus the linker, half-life 6–8 days, produces sustained GH elevation.

Four buyer checks for CJC-1295

The general eight peptide-buyer criteria all apply. These four matter more for CJC-1295:

1. The label must say DAC or no-DAC

This is the single most important check. The vial and the CoA both have to tell you which variant you bought. No-DAC has CAS number 863288-34-0. DAC has a separate CAS registration.

A vendor selling “CJC-1295” without disambiguating is failing the most basic identity disclosure. Walk away.

2. The discontinuation history matters

ConjuChem halted CJC-1295 DAC clinical development around 2007. Public reporting attributes the decision in part to broader scrutiny of ConjuChem’s DAC pipeline after a fatal adverse event in a separate trial of CJC-1131, a different DAC-modified peptide.

The program was never revived. CJC-1295 has no current pharmaceutical sponsor. A vendor making clinical claims (“treats GH deficiency,” “reverses aging”) is in FDA enforcement territory.

3. Mass-spec must match the variant

For no-DAC, the theoretical mass is 3367.9 g/mol. The formula is C152H252N44O42. Peptides this big usually show up in mass-spec as multi-charge ions: observed [M+2H]2+ near 1684.9, or [M+3H]3+ near 1123.6. The calculated neutral mass should land at 3367.9 within standard tolerance.

The DAC variant has a different molecular weight because the linker adds mass. A CoA that reports 3367.9 for a vial labeled DAC is internally inconsistent — don’t buy from that vendor.

4. Storage and shipping are unforgiving

CJC-1295 ships lyophilized (freeze-dried) and stores at −20°C long-term. Once you reconstitute it, the no-DAC form has a usable window of about 30 days refrigerated at 2–8°C. That’s shorter than BPC-157 because CJC-1295 degrades faster in solution.

Vendors who sell pre-mixed liquid at room temperature are selling a product with a shelf life measured in days. The powder is what ships reliably.

Where this falls short: The published CJC-1295 evidence is thinner than vendors imply. Recent (2020–2026) PubMed literature is dominated by anti-doping detection methods, not efficacy trials. The DAC clinical program halted in 2007 and never produced a Phase III readout. There’s a small 2026 mouse-model paper on the CJC-1295 + ipamorelin stack reducing glucocorticoid-induced muscle loss, but no controlled human study has confirmed it. Buy CJC-1295 for what it is: a research GHRH analog with a stalled clinical history and a strong WADA detection profile.

CJC-1295 (no DAC)

Modified GRF 1-29 29 aa ~30 min t½

The no-DAC variant cited across the 2021–2024 anti-doping detection literature including Memdouh et al., 2021 and the 2026 JAAOS therapeutic peptides review. CAS 863288-34-0, MW 3367.9 g/mol, ≥99% HPLC purity, third-party CoA on every lot.

View CJC-1295

2026 pricing benchmarks

CJC-1295 sits in the middle of the research-peptide cost curve. It’s longer than BPC-157 (15 aa) but shorter than tesamorelin (44 aa). The DAC modification adds synthesis cost on top of the no-DAC form. We checked US research supplier product pages on November 17, 2026. Listed single-vial prices, before shipping and codes:

  • No-DAC, 5 mg vial: $20.00–$46.00 ($4.00–$9.20 per mg). Standard retail size.
  • No-DAC, 10 mg vial: $59.99–$110.00 ($6.00–$11.00 per mg).
  • DAC vials: priced higher than no-DAC. The conjugation step adds complexity. Less commonly stocked.
  • Multi-vial tiers: some suppliers discount larger orders.

The full table, with each supplier and source, is on our peptide price list.

A price far below the rest of the market deserves a question, for either form. Each additional coupling step in a 29-amino-acid peptide is an opportunity for incomplete reaction. That means more impurities at the cheap end, where the purification step gets shortcut.

Yes, as a research reference compound. It’s not FDA-approved, never finished clinical development, and appears on FDA’s list of compounding substances that may present significant safety risks (its nomination was withdrawn). That doesn’t affect research sales.

Three more things the legal status does:

  • It tells you about the evidence base. No active pharmaceutical sponsor means no ongoing trials. Recent PubMed literature from 2020 to 2026 is dominated by anti-doping detection methods.
  • It closes the compounding pharmacy channel. Pharmacies can’t prepare CJC-1295 for human use.
  • It triggers WADA prohibition under Category S2. Validated LC-MS/MS methods detect CJC-1295 at sub-ng/mL in urine (Memdouh et al., 2021; Coppieters et al., 2022). Athletes are reliably detectable for no-DAC within hours and DAC for days.

Research-use sales operate under 21 CFR § 809.10(b)(9). Laboratory research stays legal. See peptides and the 2023 503A categorization for the deeper regulatory context.

Red flags specific to CJC-1295

Seven warning signs we’d skip:

  • “CJC-1295” without DAC/no-DAC on the label. The single most basic identity disclosure.
  • “CJC-1295 Pro,” “Long-Acting,” or branded variant names. The two real molecules are no-DAC and DAC. Anything else without a published structure is marketing.
  • Pre-mixed liquid at room temperature. Shelf life in days, not weeks.
  • Clinical claims on the product page. “Treats GH deficiency” or “reverses aging” are FDA enforcement territory for a discontinued-program compound.
  • Missing CAS number. 863288-34-0 (no-DAC) should resolve in PubChem in 30 seconds.
  • Mass-spec result that doesn’t match the variant. No-DAC = 3367.9, or [M+2H]2+ near 1684.9.
  • Vendor’s in-house QC instead of third-party testing. Independent ISO 17025 verification is the research-grade standard.
Figure 1

CJC-1295 DAC vs no-DAC — the variables a buyer should be able to compare.

The two CJC-1295 variants are different molecules with different half-lives, different prices, and different pharmacology profiles. A vendor selling “CJC-1295” without distinguishing them is failing the basic identity disclosure. The no-DAC form is what most current research-community work uses; the DAC form is the variant whose clinical program was halted.

no-DAC midpoint DAC variant Half-life ~30 min ~6–8 days Sequence length 29 aa 30 aa + DAC Price (5 mg vial) $20–46 Higher Study admin. interval Daily+ Weekly GH-release profile Pulsatile (natural) Sustained Clinical program Never developed Halted ~2007 WADA detection Hours window Days–weeks window

Source: variant characterization from the 2021 GHRH-analog detection review (Memdouh et al., 2021), 2026 JAAOS therapeutic peptides review (Rahman et al., 2026), and Vitrapep catalog pricing 2026.

CJC-1295 (no DAC)

10 mg ≥99% pure Lyophilized

Modified GRF 1-29, CAS 863288-34-0, MW 3367.9 g/mol. The same reference compound used across the 2020–2024 anti-doping detection literature and grouped in the 2026 Sports Medicine review of unapproved peptide therapies. COA with HPLC trace and mass-spec ships with every order.

Learn more

Frequently asked questions

Is CJC-1295 legal to buy?

Yes, as a research reference compound. It’s not FDA-approved, never finished clinical development, and appears on FDA’s list of compounding substances that may present significant safety risks. That doesn’t close research sales. It’s also on the WADA Prohibited List (S2).

DAC vs no-DAC — which one?

Two different molecules. DAC adds an albumin-binding linker that stretches the half-life to 6–8 days. No-DAC (Modified GRF 1-29) has a 30-minute half-life. Most current research use is the no-DAC form because it preserves pulsatile GH release. If the listing says only “CJC-1295,” ask before you buy.

How much does CJC-1295 cost?

On November 17, 2026, US research suppliers listed no-DAC CJC-1295 (Mod GRF 1-29) at $20.00–$46.00 per 5 mg vial and $59.99–$110.00 per 10 mg vial ($4.00–$11.00 per mg). The DAC variant costs more because the linker-conjugation step adds synthesis complexity. Far below that range, purity is the trade-off. Our peptide price list has the full table.

Why was CJC-1295 DAC discontinued?

ConjuChem halted clinical development around 2007. Public reporting attributes the decision in part to scrutiny of the broader DAC pipeline after a fatal adverse event in a separate trial of CJC-1131. The program never restarted and CJC-1295 has no current sponsor.

CJC-1295 vs Ipamorelin

Different signaling pathways, complementary effects. CJC-1295 acts on the GH-releasing pathway. Ipamorelin acts on the ghrelin pathway and also blocks somatostatin, the brake on GH. Researchers stack them because the two pathways combine well. A 2026 review showed the combination improved muscle force in mouse models of glucocorticoid-induced muscle loss (Mayfield et al., 2026). See the CJC-1295 vs Ipamorelin comparison.

What should a CJC-1295 CoA show?

For no-DAC: CAS 863288-34-0, HPLC purity above 98% with chromatogram, mass-spec at MW ~3367.9 g/mol. The mass usually shows as multi-charge ions [M+2H]2+ near 1684.9 or [M+3H]3+ near 1123.6. Water content should be 2–8% by Karl Fischer titration. Counterion content is usually TFA at 5–15%. The DAC variant has a different MW because of the linker. The lab should be ISO 17025-accredited and named.

What to know now

  • Two variants, not one. Confirm DAC vs no-DAC before purchase. Different half-lives, prices, pharmacology.
  • No-DAC: CAS 863288-34-0, MW 3367.9 g/mol. The numbers a credible CoA shows for Modified GRF 1-29.
  • $20.00–$46.00 per 5 mg no-DAC vial on November 17, 2026. DAC costs more because the linker adds synthesis steps.
  • Clinical development halted around 2007. No current pharmaceutical sponsor.
  • WADA S2 with validated detection. Athletes are reliably detectable at sub-ng/mL.
  • Lyophilized powder is the literature form. Room-temperature liquid has a much shorter window.
  • Recent literature is dominated by detection methods. No new efficacy RCTs in the 2020–2026 window.

What we’re watching

The big signal: whether any developer revives a clinical program for CJC-1295. Two decades after the ConjuChem halt, no sponsor has emerged. Without one, efficacy data won’t accumulate and the literature stays anchored on analytical chemistry. A secondary signal: whether the longer-acting GHRH-analog class (which includes tesamorelin) finds any new approved indication beyond HIV-associated lipodystrophy. That would shift the regulatory framing for the entire receptor target. We’re also watching FDA enforcement against vendors making clinical claims about CJC-1295 — the discontinued-program status and bulks-list placement put those vendors at higher risk.

Also in the library

More for endocrine & metabolism

All 38 compounds for endocrine & metabolism

Sources: Memdouh 2021, Drug Testing and Analysis; Rahman 2026, JAAOS: Global Research and Reviews; Sinha 2020, Translational Andrology and Urology; Coppieters 2022, Journal of Pharmaceutical and Biomedical Analysis; Mayfield 2026, The American Journal of Sports Medicine; Mendias 2026, Sports Medicine; Coutinho 2026, The Journal of Sports Medicine and Physical Fitness; U.S. Food and Drug Administration 2023, Section 503A of the Federal Food, Drug, and Cosmetic Act; World Anti-Doping Agency 2026, The Prohibited List; International Organization for Standardization 2017. All 10 citations

Back to the research library

References

  1. Memdouh, S., Gavrilović, I., Ng, K., Cowan, D., & Abbate, V. (2021). Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Testing and Analysis, 13(11–12), 1871–1887. https://doi.org/10.1002/dta.3183
  2. Rahman, M., Mojica, E. S., Vasireddi, N., et al. (2026). Therapeutic peptides in orthopaedics: Applications, challenges, and future directions. JAAOS: Global Research and Reviews. https://doi.org/10.5435/JAAOSGlobal-D-25-00236
  3. Sinha, D. K., Balasubramanian, A., Tatem, A. J., et al. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology, 9(Suppl 2), S149–S159. https://doi.org/10.21037/tau.2019.11.30
  4. Coppieters, G., Deventer, K., Polet, M., Van Eenoo, P., & Judák, P. (2022). An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS. Journal of Pharmaceutical and Biomedical Analysis, 214, 114726. https://doi.org/10.1016/j.jpba.2022.114726
  5. Mayfield, C. K., Bolia, I. K., Feingold, C. L., et al. (2026). Injectable peptide therapy: A primer for orthopaedic and sports medicine physicians. The American Journal of Sports Medicine. https://doi.org/10.1177/03635465251357593
  6. Mendias, C. L., & Awan, T. M. (2026). Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Medicine. https://doi.org/10.1007/s40279-026-02437-0
  7. Coutinho, D., Reis, M., Carvalho, M., et al. (2026). A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. The Journal of Sports Medicine and Physical Fitness. https://doi.org/10.23736/S0022-4707.26.17773-1
  8. U.S. Food and Drug Administration. (2023). Section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/drugs/human-drug-compounding/section-503a-federal-food-drug-and-cosmetic-act
  9. World Anti-Doping Agency. (2026). The Prohibited List. https://www.wada-ama.org/en/prohibited-list
  10. International Organization for Standardization. (2017). ISO/IEC 17025:2017 — General requirements for the competence of testing and calibration laboratories. https://www.iso.org/standard/66912.html